The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
7d
StudyFinds on MSNJournavx: What to know about new FDA-approved non-opioid pain medicationIntroducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results